Almanack Investment Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Almanack Investment Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,823	Closed	-$101K	–	183
2024 Q3	$101K	Hold	13,823	–	–	0.02%	177
2024 Q2	$78.9K	Hold	13,823	–	–	0.01%	177
2024 Q1	$69.3K	Hold	13,823	–	–	0.01%	175
2023 Q4	$124K	Hold	13,823	–	–	0.02%	155
2023 Q3	$107K	Hold	13,823	–	–	0.02%	156
2023 Q2	$134K	Hold	13,823	–	–	0.02%	164
2023 Q1	$152K	Hold	13,823	–	–	0.03%	162
2022 Q4	$59.7K	Sell	13,823 -100	-0.7%	-$580	0.01%	169
2022 Q3	$104K	Hold	13,923	–	–	0.02%	182
2022 Q2	$140K	Hold	13,923	–	–	0.01%	433
2022 Q1	$172K	Buy	13,923 +4,159	+43%	+$64.3K	0.01%	458
2021 Q4	$223K	Buy	+9,764	New	+$231K	0.02%	446

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Almanack Investment Partners's AUPH Position: Q4 2024 in Review

Almanack Investment Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 13,823 shares — an estimated $101K sold.

Almanack Investment Partners first reported a position in AUPH in Q4 2021 and held it in 12 quarters. The position peaked at $223K in Q4 2021. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

Almanack Investment Partners reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Almanack Investment Partners sold 13,823 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $101K.
Almanack Investment Partners first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 12 quarters.
Almanack Investment Partners's Aurinia Pharmaceuticals position peaked at $223K in Q4 2021.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Almanack Investment Partners's 13F filing for Q4 2024, filed 28 Jan 2025.